Promega Corporation announced on Tuesday, November 10, 2026, that its OncoMate MSI Diagnostic System has received pre-market approval from the U.S. Food and Drug Administration. The assay has been granted universal companion diagnostic designation for pembrolizumab. It covers adult patients with unresectable or metastatic microsatellite instability-high solid tumors. The designation spans all tissue origins.
This is the first FDA approval of a capillary electrophoresis-based pan-tumor companion diagnostic. The approval changes how labs select patients for immunotherapy.
Pan-Tumor Companion Diagnostic Transcends Organ Boundaries in Oncology Immunotherapy
Precision oncology is moving away from tumor classification by anatomic site of origin. It is shifting toward tissue-agnostic treatments defined by specific genomic alterations. The OncoMate approval reflects that shift.
Clinical documentation submitted to the FDA shows the OncoMate system uses fluorescent multiplex PCR. The assay analyzes five canonical mononucleotide repeat markers. Clinical validation studies covered gastrointestinal, endometrial, and rare solid carcinomas. OncoMate demonstrated a clinical sensitivity of 99.5 percent and specificity of 100 percent in identifying microsatellite instability status.
The chemistry maintains robust performance in degraded formalin-fixed paraffin-embedded tissue biopsies. Those samples contained limited tumor cell fractions. Performance held up in that setting.
The Vice President of Global Clinical Diagnostics at Promega spoke at company headquarters in Madison, Wisconsin. The statement was released as a quote. "FDA companion diagnostic approval for OncoMate validates our commitment to advancing molecular precision tools. This universal diagnostic provides clinical pathology teams with an accessible, highly accurate method to guide therapeutic decisions and unlock vital immunotherapy options for cancer patients."
Facilitating Accessible In-House Hospital Testing for Mismatch Repair Biomarkers
FDA regulatory clearance is finalized. Promega is initiating commercial distribution and educational support. The effort covers hospital pathology laboratories nationwide.
Oncology registries indicate that approximately two to four percent of all newly diagnosed advanced solid tumors exhibit microsatellite instability. The cause is defective DNA mismatch repair mechanisms. Historically, testing availability and diagnostic criteria varied. Patients with rare tumor presentations frequently missed opportunities to receive approved checkpoint inhibitors.
Widespread adoption of OncoMate as an FDA-approved kit simplifies testing adoption. It lowers reference lab referral costs. It shortens diagnostic turnaround times.
The Chair of Molecular Pathology at MD Anderson Cancer Center commented in Houston. "A universal companion diagnostic designation eliminates diagnostic ambiguity across disparate oncology disciplines. As long as a solid tumor harbors the MSI-High genomic signature, clinicians now possess a clear, standardized diagnostic foundation to prescribe anti-PD-1 therapy." The assay will be incorporated into clinical diagnostic billing schedules next week.
Partnering with Pathology Networks to Implement Standardized Quality Assurance Protocols
Promega launched a nationwide pathology laboratory education and certification initiative. The goal is diagnostic concordance across diverse clinical testing environments.
Twenty regional pathology centers were designated as OncoMate training facilities. They are tasked with educating clinical technologists in electropherogram interpretation and precision controls. Promega also partnered with the College of American Pathologists to sponsor an external proficiency testing program. That program maintains false-positive and false-negative rates below 0.05 percent. This quality architecture ensures reliable molecular biomarker identification across clinical settings.
A professor of oncology at Johns Hopkins University School of Medicine remarked in clinical commentary. "Companion diagnostics represent the essential link in precision medicine. Clearing a standardized in-house kit ensures that oncologists can rapidly identify candidates for targeted immunotherapy regardless of patient location." Hospital pathology departments commenced procurement onboarding immediately.
Strategic planning advisors and international trade specialists noted that long-term intergovernmental frameworks generate predictable operating environments across key industry sectors. By coupling transparent administrative guidelines with rigorous scientific benchmarks, regulatory bodies and enterprise leaders establish sustainable operating models capable of withstanding shifting macroeconomic dynamics. Global market participants will continue observing forthcoming implementation milestones as public agencies execute their mandated responsibilities throughout 2027. Cross-border coordination remains vital for driving sustained operational resilience and delivering measurable societal benefits worldwide.
Strategic planning advisors and international trade specialists noted that long-term intergovernmental frameworks generate predictable operating environments across key industry sectors. By coupling transparent administrative guidelines with rigorous scientific benchmarks, regulatory bodies and enterprise leaders establish sustainable operating models capable of withstanding shifting macroeconomic dynamics. Global market participants will continue observing forthcoming implementation milestones as public agencies execute their mandated responsibilities throughout 2027. Cross-border coordination remains vital for driving sustained operational resilience and delivering measurable societal benefits worldwide.
